Two-year structural skeletal outcomes of burosumab therapy in pediatric X-linked hypophosphatemia: A radiographic cohort study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of children's orthopaedics"
DOI: 10.1177/18632521251398403
Abstract: Purpose X-linked hypophosphatemia is characterized by skeletal abnormalities, particularly lower limb angular deformities. Although burosumab has demonstrated short-term clinical improvements, its mid- to long-term effects on skeletal alignment remain underexplored. This study evaluated skeletal outcomes… read more here.
Keywords: linked hypophosphatemia; lateral distal; burosumab therapy; pediatric linked ... See more keywords
Two Cases of Tumor-induced Osteomalacia Resulting in Surgical Resection during Burosumab Therapy
Sign Up to like & getrecommendations! Published in 2025 at "Internal Medicine"
DOI: 10.2169/internalmedicine.4958-24
Abstract: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome that results from tumors that secrete fibroblast growth factor 23 (FGF23). This leads to chronic hypophosphatemia. Burosumab, an anti-FGF23 antibody, is an effective treatment when surgery is… read more here.
Keywords: tumor induced; tumor; burosumab therapy; induced osteomalacia ... See more keywords
Cardiovascular health in pediatric patients with X-linked hypophosphatemia under two years of burosumab therapy
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2024.1400273
Abstract: Introduction X-linked hypophosphatemia (XLH) is caused by an inactivating mutation in the phosphate-regulating endopeptidase X-linked (PHEX) gene whose defective product fails to control phosphatonin fibroblast growth factor 23 (FGF23) serum levels. Although elevated FGF23 levels… read more here.
Keywords: treatment; linked hypophosphatemia; burosumab therapy; study ... See more keywords